Culture Biosciences, OneProjects, Sciwind Biosciences
Abalos Therapeutics Raises €32.5M in Series A Extension
Abalos Therapeutics, a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in Series A extension round.
This additional round, which brings the total raised to date to €43m (USD50m), was led by Seventure Partners with participation from Coparion, Ventura BioMed Investors and Hx Bio Ventures as well as existing investors including Boehringer Ingelheim Venture Fund (BIVF), Gründerfonds Ruhr, NRW.BANK and High-Tech Gründerfonds (HTGF).
The company intends to use the funds to advance its first product candidate into a Phase 1/2 trial in multiple solid tumors including the expansion cohorts to demonstrate early signs of clinical efficacy as well as fund further pipeline expansion.
Led by Dr. Marcus Kostka, CEO, Abalos Therapeutics is advancing a technology platform that harnesses the unique features of the lymphocytic choriomeningitis virus (LCMV), which specifically targets tumor cells. Through its proprietary Fast Evolution Platform, the company is generating variants with optimized anti-tumoral properties to trigger a highly precise and directed immune response that can be utilized for distant metastases and enable long-term disease control.
Abalos Therapeutics Raises €32.5M in Series A Extension
Abalos Therapeutics, a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in Series A extension round
OneProjects Raises $17M in Financing
OneProjects, a Dublin, Ireland and Munich, Germany-based developer of four-dimensional (4D) cardiac imaging technology, raised $17m in financing.
The round included an $8m Series A2 financing and two grants worth $9m.
The Series A2 financing was led by imec.xpand, with participation from the European Innovation Council (EIC) Fund and existing investors, including LSP and Atlantic Bridge Ventures.
Originating from Bioinnovate Ireland and spun out of Trinity College Dublin, the company will use the new funds to complete product development, conduct clinical trials, gain FDA clearance and prepare for U.S. commercialization of the first product developed from its proprietary 4D cardiac imaging platform, VERAFEYE™.
Co-founded by CEO Fionn Lahart and CTO Christoph Hennersperger in 2017, OneProjects designs and develops an innovative 4D imaging platform for cardiac applications that operates at the intersection of hardware, software, and data science. This technology is designed to improve the treatment of atrial fibrillation and other cardiac arrhythmias, and can also be applied to benefit structural heart procedures.
OneProjects Raises $17M in Financing - FinSMEs
OneProjects, a Dublin, Ireland and Munich, Germany-based developer of four-dimensional (4D) cardiac imaging technology, raised $17m in financing
Rejuvenate Biomed Raises EUR 15.7M in Series B Funding
Rejuvenate Biomed NV, a Heusden-Zolder, Belgium-based biomedical company developing novel combination drugs for age-related diseases, raised EUR 15.7m in Series B funding.
The round was led by Rejuveron Life Sciences AG and Luxembourg-based Vesalius Biocapital.
The company intends to use the funds to is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Established in October 2017 by Ann Beliën, PhD, after nearly two decades of experience with Janssen Pharmaceutical companies of Johnson and Johnson, Rejuvenate is developing safe, proprietary, combination drugs that delay or prevent the onset of multiple age-related diseases, with a focus on the intersection between fundamental aging mechanisms and chronic conditions. The company has developed a proprietary in silico screening platform that uses an approach based on artificial intelligence and network biology to investigate dysregulated pathways in aging. With this platform, the company is able to evaluate if safe, marketed treatments can be used as synergistic drug combinations to impact upon these pathways, maintaining natural cellular resilience and postponing the onset of certain age-related diseases.
Rejuvenate Biomed Raises EUR 15.7M in Series B Funding
Rejuvenate Biomed NV, a Heusden-Zolder, Belgium-based biomedical company developing novel combination drugs for age-related diseases, raised EUR 15.7m in Series B funding
AceCann Closes $15M Seed Financing Round
AceCann, a Lisbon, Portugal based medical cannabis company, closed a $15M (USD) Seed financing.
The round was led by venture firm Casa Verde with participation from Lince Capital, Chris Mayle and Marc Gare, co-founders of Advanced Grow Labs (acquired by GTI); Frank Cid, CEO of Royal Life Centers; and angel investor Sebastian de la Rosa of Whistler Medical Marijuana Corporation (acquired by Aurora), along with public funding and debt capital.
The company will use the proceeds to develop a production facility located in Vendas Novas, Portugal dedicated to the organic cultivation, processing and extraction of premium medical cannabis products. Construction started in September.
Led by CEO Pedro Gomes, AceCann is a medical cannabis company focused on the cultivation, processing, extraction and R&D of organic medical cannabis. Through its focus on smaller, scalable, indoor farming methods, the company will be able to precisely manage temperature, humidity and other variables to ensure each plant receives daily care while meeting the quality standards associated with premium medical cannabis products. AceCann is the first company in Portugal to be awarded an R&D certificate of suitability by the National Innovation Agency.
AceCann Closes $15M Seed Financing Round
AceCann, a Lisbon, Portugal based medical cannabis company, closed a $15M (USD) Seed financing
Bond Vet Receives $170M Growth Investment from Warburg Pincus
Bond Vet, a NYC-based tech-enabled brand of veterinary care clinics, received $170m investment from Warburg Pincus.
The funding will be used to expand the company’s footprint and invest in equipment, training, culture and technology to further improve the clinical experience for veterinarians, pets and pet parents alike.
Led by Mo Punjani, Co-Founder and CEO, and Dr. Zay Satchu, Co-Founder and Chief Veterinary Officer, Bond Vet offers a convenient experience for veterinary care, with clinics providing a wide range of appointment options including pre-scheduled appointments, walk-in visits, and telehealth. Its services span from wellness checkups and traditional GP offerings to urgent care, such as wound treatment, GI issues and mass removals.
Since its inception in June of 2019, Bond Vet has treated more than 40,000 pets in the New York City area.
Bond Vet Receives $170M Growth Investment from Warburg Pincus
Bond Vet, a NYC-based tech-enabled brand of veterinary care clinics, received $170m investment from Warburg Pincus
Rectify Pharmaceuticals Raises $100M in Series A Financing
Rectify Pharmaceuticals, Inc., a Cambridge, Mass.-based biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, closed a $100m Series A financing.
The round was co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
The company plans to use the capital to conduct its first human proof-of-concept (POC) studies.
Led by Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture, and Jonathan Moore, Ph.D., Chief Scientific Officer, and founder, Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas.
https://www.finsmes.com/2021/10/rectify-pharmaceuticals-raises-100m-in-series-a-financing.html
Culture Biosciences Raises $80M in Series B Funding
Culture Biosciences, a South San Francisco, CA-based company enabling biotech firms to develop and scale manufacturing processes in the cloud, raised $80m in Series B financing.
The round was led by Northpond Ventures with participation from Synthesis Capital and existing investors Cultivian Sandbox Ventures, The Production Board, Craft Ventures, E14 Fund, Box Group, Verily Life Sciences, and Section 32. In conjunction with the funding, Andrew Lee, Ph.D., of Northpond Ventures will join Culture’s Board of Directors.
Led by Will Patrick, CEO and co-founder, Culture Biosciences is a technology company offering biotechnology companies a way to do biomanufacturing R&D. By leveraging its cloud bioreactor platform, bioprocess scientists can spend more time designing and analyzing experiments. Culture’s cloud bioreactors offer full control of experimental design and allow real-time monitoring and process changes. Beyond generating data more quickly, the platform provides advanced data visualization and analytics tools to generate new insights into bioprocesses.
Culture Biosciences Raises $80M in Series B Funding
Culture Biosciences, a South San Francisco, CA-based company enabling biotech firms to develop and scale manufacturing processes in the cloud, raised $80m in Series B financing
DeepSight Technology Raises $25M in Series A Funding
DeepSight Technology, a San Francisco Bay Area-based augmented diagnostic medical imaging company, raised $25m in Series A funding.
The round was led by Deerfield Management Company, a healthcare investment firm, with additional funding from Wing, Alter Venture Partners, and Time BioVentures.
Led by founder and CEO Nader Sadrzadeh, DeepSight is augmenting diagnostic medical imaging with the introduction of novel ultrasound technology, using patented hardware, software, and AI algorithms to deliver high sensitivity and to more than double the effective range.
DeepSight Technology Raises $25M in Series A Funding
DeepSight Technology, a San Francisco Bay Area-based augmented diagnostic medical imaging company, raised $25m in Series A funding
Oshi Health Raises $23M in Series A Funding
Oshi Health, a NYC-based virtual specialty care company focused on gastrointestinal (GI) health, raised $23m in Series A funding.
The round was co-led by Flare Capital Partners, Bessemer Venture Partners and Frist Cressey Ventures with a strategic investment from CVS Health Ventures. Takeda Digital Ventures, which has funded the company since its inception, participated in the round along with health industry veterans, including author and athenahealth cofounder Jonathan Bush, Nat Turner and Zach Weinberg of Operator Partners and Flatiron Health, serial healthcare entrepreneur and IBD patient advocate Eric M. Stone, and Russell Glass, the CEO of Headspace Health.
The company intends to use the funds to scale its virtual-first, integrated approach to GI care delivery.
Led by Oshi Health CEO Sam Holliday, Oshi Health provides a redesigned gastrointestinal care experience via a virtual, patient-centered care delivery model built to provide diagnosis and multidisciplinary care for GI conditions, and to empower people to gain significant and lasting control of their symptoms and improve their quality of life. Its evidence-based, whole-person care protocols can diagnose patients and provide treatment, including often-neglected dietary and psychosocial interventions.
Oshi Health Raises $23M in Series A Funding
Oshi Health, a NYC-based virtual specialty care company focused on gastrointestinal (GI) health, raised $23m in Series A funding
Senior-focused startup Lifespark scores $20M
This morning senior-focused health tech company Lifespark scored $20 million in Series B funding. Virgo-Managed Fund and Medicare Advantage provider UCare led the round.
This comes roughly a year after the Minneapolis-based company raked in $16 million, according to Crunchbase.
The company developed a tech-backed holistic system focused on healthy aging. Seniors are able to get a “life plan” that includes long-term and short-term goals aimed at giving the person more independence. Patients are able request a clinician visit at home or complete a video visit.
Its technology includes a population health platform aimed at removing silos. The system, which it calls an electronic life record, includes a professional portal, the life plan, prescriptive signals, a 360 patient view, and analytics and insights, as well as offering a member and family experience.
The company said it plans to use the new funds to build out its operating system and technology platform.
Senior-focused startup Lifespark scores $20M | MobiHealthNews
The company offers a system that aims to break down healthcare silos.
TwelveStone Health Partners Receives $12M From Siena Healthcare Finance
TwelveStone Health Partners, a provider of comprehensive chronic care medication services, received $12M in funding from Siena Healthcare Finance.
The investment will be used to expand the company’s footprint of infusion center locations serving specialty practices and patients in markets across Tennessee and the Southeast.
Led by Shane Reeves, chief executive officer, TwelveStone Health Partners supports the transition from acute to post-acute care environments and the transition from sickness to health, offering a service to patients with chronic conditions including a headquarters location in Murfreesboro and infusion centers in Murfreesboro, TN, Canton, GA, Chattanooga, TN, Knoxville, TN, and Mt. Juliet, TN. A new location in Spring Hill, TN is scheduled to open within the next month.
TwelveStone Health Partners Receives $12M From Siena Healthcare Finance
TwelveStone Health Partners, a provider of comprehensive chronic care medication services, received $12M in funding from Siena Healthcare Finance
Better Health Raises $10M in Series A Funding
Better Health, a San Francisco CA-based medical provider, raised $10M in Series A funding.
The round was led by Caffeinated Capital and General Catalyst with participation from Bill Ackman’s family office, Table Management, 8VC, Anorak Ventures, Tank Hill Venture Partners, Motive Science, Modern Ventures and Unpopular VC.
The company intends to use the funds to build out its capabilities to include specialized telehealth services covered by insurance, expand its model of bundled supplies, education and telehealth into new categories of products and chronic conditions, and expand its partnerships with health systems and payers.
Led by Naama Stauber Breckler and Adam Breckler, Better Health is a new type of healthcare provider offering an end-to-end chronic condition care solution, bundling peer-support, education, telehealth, and home delivery of medical supplies. The company currently operates in 46 states and its services are covered by insurance for more than 81M lives across the country. Its insurance partners include Medicare, Medicaid, Oscar Health, and Humana, among other payers.
Better Health Raises $10M in Series A Funding - FinSMEs
Better Health, a San Francisco CA-based medical provider, raised $10M in Series A funding.
Sciwind Biosciences Raised $70M in Series C Funding
Sciwind Biosciences, a Hangzhou, China and San Francisco CA-based clinical-stage biopharmaceutical company, raised $70M in Series C funding.
The round was led by Financing Supported by IDG Capital, Loyal Valley Capital and LYFE Capital.
Led by Dr. Hai Pan, Founder and CEO, Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic diseases. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates. Sciwind also developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutics delivery platforms and has identified multiple drug candidates based on these core platform technologies.
https://www.finsmes.com/2021/10/sciwind-biosciences-raised-70m-in-series-c-funding.html
AUM Biosciences Raises USD$27M in Series A Funding
AUM Biosciences, a Singapore-based biotech company, raised USD$27M in Series A funding.
The round was led by Everlife with participation from SPRIM Global Investment.
The company intends to use the funds to accelerate pipeline development and expansion and business growth.
Led by Vishal Doshi, CEO, and Harish Dave, CMO, AUM Biosciences is a clinical stage biotech company focused on discovering and developing novel targeted oncology therapies, particularly for cancers.
AUM Biosciences Raises USD$27M in Series A Funding - FinSMEs
AUM Biosciences, a Singapore-based biotech company, raised USD$27M in Series A funding
Navina Secures $15M in Series A Funding
Navina, a Tel Aviv, Israel-based developer of AI-powered clinical platform for primary care, secured $15m in Series A funding.
The round, which brought total funding to date to $22m, was led by Vertex Ventures Israel with participation from Schusterman Family Investments (SFI) and existing investor Grove Ventures.
The company intends to use the funds to accelerate investment in its AI technology, and expand within physician groups and the enterprise healthcare market.
Led by Ronen Lavi, co-founder and CEO, Navina uses medically-informed AI to replace disorganized patient data with an intuitive Patient Portrait – a logical grid that makes it possible for every primary care physician to assess even the most complex cases in minutes. The platform has already demonstrated measurable clinical and economic impact for multi-specialty and primary care physician groups nationwide. Since adopting the system, groups are seeing increases in HCC-RAF (Risk Adjustment Factor) scores, which translates into revenue.
Navina Secures $15M in Series A Funding
Navina, a Tel Aviv, Israel-based developer of AI-powered clinical platform for primary care, secured $15m in Series A funding
Anticancer Bioscience Raises Additional USD 10.6M; Closes Over $31M Seed Round
Anticancer Bioscience, a Chengdu, China-based developer of synthetic lethal approaches to precision oncology, secured an additional CNY 68.4m (~USD 10.6m) in seed extension financing.
The round was led by Three Rivers Capital, who joined existing private Chinese investors. The total raised in the seed round is now over USD31m (around CNY 200m).
The proceeds will be mainly used to accelerate the preclinical development of the company’s two most advanced programs, MYC-synthetic lethal and contact inhibition restoration. The funds will also be used to optimize lead compounds for polyploidy-synthetic lethal therapy and to identify additional lead compounds for its contact inhibition restoration approach to combatting cancer.
Led by Dun Yang PhD, Founder, President, and CEO, Anticancer Bioscience is an international private company, commercializing discoveries emerging from cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China.
Anticancer Bioscience Raises Additional USD 10.6M; Closes Over $31M Seed Round
Anticancer Bioscience, a Chengdu, China-based developer of synthetic lethal approaches to precision oncology, secured an additional CNY 68.4m (~USD 10.6m) in seed extension financing
Perx Health Raises USD$2.2M in Seed Funding
Perx Health, an Australian digital health startup, raised $3m in AUD ($2.2M USD) seed funding.
The round was led by AirTree Ventures.
The company intends to use the funds to expand into the U.S.
Launched in 2017 by Scott Taylor, CEO, Perx provides a behavior change platform that helps people with chronic health conditions like diabetes and complex behavioral health conditions adhere to daily treatment plans. Perx offers a single solution that works across any condition (or multiple conditions) managed by patients, including diabetes, cardiovascular, behavioral and mental health, respiratory, and musculoskeletal conditions, as well as less prevalent conditions like Hepatitis C and HIV. It has also been validated for patients with complex social determinants of health, such as vulnerable public hospital patients with multiple chronic conditions and a government-sponsored program for higher-risk Indigenous Australians living with COVID-19.
